A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy

Sponsor
Suven Life Sciences Limited
Study ID
NCT07540364
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Samelisant — DRUG
    Tablet dosage form, once a day
  • Placebo — DRUG
    Matching placebo tablets, once a day

Study Details

The primary objective of this study is to evaluate the effect of Samelisant on excessive daytime sleepiness (EDS) after 12 weeks of treatment. In addition, the study aims to assess its effectiveness in influencing the weekly frequency of cataplexy episodes (sudden bouts of muscle weakness) that occur while the individual remains conscious. Other objectives include examining the impact of Samelisant on attention and alertness, overall quality of life, the spectrum of narcolepsy symptoms, and daily functioning, as well as evaluating its safety profile.

Key Dates

Start date
Jun 19, 2026
Status verified
Apr 2026
Primary completion
Nov 19, 2027
Completion
Dec 19, 2027

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Samelisant Tablets
  • Placebo Comparator: Placebo Tablets

Primary Outcome Measure

Change from Baseline in total Epworth Sleepiness Scale (ESS) score at Week 12 [ Time Frame: Baseline to Week 12 ]

Central Contacts

Related Studies